Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk

Authors Ajikumar V Aryangat, John E Gerich

Published 9 March 2010 Volume 2010:6 Pages 145—155


Review by Single-blind

Peer reviewer comments 4

Ajikumar V Aryangat, John E Gerich
University of Rochester, Rochester, New York, USA
Abstract: Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in  patients with type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes in patients with type 2 diabetes. Treatment options, including the new dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 mimetics that primarily target postprandial hyperglycemia, are also discussed. Hyperglycemia increases cardiovascular mortality, and reducing hyperglycemia lowers cardiovascular risk parameters. Control of both fasting and postprandial hyperglycemia is necessary to achieve optimal glycated hemoglobin control. Therefore, antihyperglycemic agents that preferentially target postprandial hyperglycemia, along with those that preferentially target fasting hyperglycemia, are strongly suggested to optimize individual diabetes treatment strategies and reduce complications.
Keywords: postprandial hyperglycemia, diabetes mellitus, drugs, cardiovascular risk

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Readers of this article also read:

Time-dependent effect in green synthesis of silver nanoparticles

Darroudi M, Ahmad MB, Zamiri R, Zak AK, Abdullah AH, Ibrahim NA

International Journal of Nanomedicine 2011, 6:677-681

Published Date: 5 April 2011

Argatroban in the management of heparin-induced thrombocytopenia

Luciano Babuin, Vittorio Pengo

Vascular Health and Risk Management 2010, 6:813-819

Published Date: 1 September 2010

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Vascular Health and Risk Management 2010, 6:671-690

Published Date: 5 August 2010

Mortality following operations for lower extremity peripheral arterial disease

Tracie C Collins, David Nelson, Jasjit S Ahluwalia

Vascular Health and Risk Management 2010, 6:287-296

Published Date: 3 May 2010

Does plasmin have anticoagulant activity?

Jane Hoover-Plow

Vascular Health and Risk Management 2010, 6:199-205

Published Date: 26 March 2010

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

Jennifer Vergara-Jimenez, Pierluigi Tricoci

Vascular Health and Risk Management 2010, 6:39-45

Published Date: 2 March 2010

Inhaled insulin: overview of a novel route of insulin administration

Lucy D Mastrandrea

Vascular Health and Risk Management 2010, 6:47-58

Published Date: 15 January 2010

Recent advances in the treatment of premature ejaculation

Kate D Linton, Kevan R Wylie

Drug Design, Development and Therapy 2010, 4:1-6

Published Date: 5 January 2010